Please assess the completion status of the following clinical trial:

Trial Title: 20070360 Incident Dialysis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adults greater than or equal to 18 years of age on hemodialysis for \> 3 and less than or equal to 12 months prior to enrollment into the study~* Mean of 2 PTH determinations during the screening period (drawn at least 2 days apart) \> 300 pg/mL (31.8 pmol/L); or biPTH \> 160 pg/mL (17.0 pmol/L)~* Mean of 2 corrected serum calcium determinations drawn on the same day as the PTH determinations greater than or equal to 8.4 mg/dL (2.1 mmol/L)~* Subject will be able to complete the study, to the best of his/her knowledge~* Before any study-specific procedure, the appropriate written informed consent must be obtained~Exclusion Criteria:~* Mean of 2 PTH determinations during the screening period (drawn at least 2 days apart) \> 800 pg/mL (84.9 pmol/L); or biPTH \> 430 pg/mL (45.6 pmol/L) AND receiving vitamin D on entering screening~* Parathyroidectomy (partial or full) less than or equal to 6 months before entering screening~* Anticipated parathyroidectomy (partial or full) within 6 months after randomization~* Have a scheduled date for kidney transplant surgery~* Received cinacalcet since initiating hemodialysis~* Have received vitamin D therapy for less than 30 days before entering screening or required a change in prescribed vitamin D brand or dose within 30 days before entering screening. If subjects are not receiving vitamin D therapy, they must remain free of vitamin D therapy for the 30 days before entering screening~* Subject is pregnant (eg, positive HCG test) or is breast-feeding~* Refusal to use highly effective contraceptive measures (as determined by the investigator) throughout the study (screening and post enrollment)~* Current gastrointestinal disorder that may be associated with impaired absorption of orally administered medications or an inability to swallow tablets~* Known sensitivity, intolerance, or other adverse response to cinacalcet which would prevent on-study treatment compliance~* Have an unstable medical condition within 30 days before screening, or otherwise unstable in the judgment of the investigator~* Subject is currently enrolled in, or fewer than 30 days prior to entering screening have passed since subject received other investigational agent(s) (devices or drug).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cinacalcet Group (Type: EXPERIMENTAL): Cinacalcet plus low dose active Vitamin D (if prescribed)
- Control Group (Type: ACTIVE_COMPARATOR): Flexible active vitamin D dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).